← Human Trials & Peer-Reviewed Studies
Supplemental vitamin D and physical performance in COPD: a pilot randomized trial.
Plain-language guide to PMID 23430315 (2013): randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 23430315
- Journal
- International journal of chronic obstructive pulmonary disease
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Bjerk SM et al. (4 authors)
- DOI
- 10.2147/COPD.S40885
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
The researchers tested the effect of vitamin D supplementation on physical performance in patients with COPD.
Who Took Part
By PubMed's age tags, the people studied were older adults, men only.
How the Study Was Run
The researchers set it up as a randomized, placebo-controlled and pilot study.
The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.
The primary outcome was the 6-week change in Short Physical Performance Battery (SPPB) score.
Secondary outcomes included changes in the St George's Respiratory Questionnaire (SGRQ) score, and serum 25(OH)D.
What Was Measured
The researchers tested the effect of vitamin D supplementation on physical performance in patients with COPD.
PubMed files the paper under topics including Cholecalciferol, Exercise Test, Gait, Linear Models, Muscle Strength, Pilot Projects and Postural Balance.
The authors tagged it with the keywords chronic obstructive pulmonary disease, randomized controlled trial, skeletal muscle strength and vitamin D.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and pilot study of Vitamin D, K2, Magnesium and Zinc.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2013 (International journal of chronic obstructive pulmonary disease), a journal based in New Zealand.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.